Róna G
First Department of Medicine (Cardiology), Municipal Hospital Ajka, Hungary.
Ther Hung. 1991;39(2):63-70.
Angiotensin converting enzyme inhibitor therapy decreases the production of the vasoconstrictive angiotensin II and reduces the degradation of certain kinines of vasodilatator action. Of captopril, enalapril, and lysinopril marketed abroad, only captopril of shorter action is available in Hungary. Angiotensin converting enzyme inhibitors are new means for the therapy of hypertension and congestive heart failure. Captopril seems to be effective at an early stage of heart failure. It slows down or even inhibits the progression of heart failure. New aspects of therapy have been revealed. It may be successfully used in angina pectoris, for the prevention of reperfusion arrhythmias accompanying myocardial infarction, for the treatment of renoparenchimal renal diseases, diabetic nephropathy. The side-effects, interactions, and dosage of angiotensin converting enzyme inhibitors have also been discussed.
血管紧张素转换酶抑制剂疗法可减少血管收缩性血管紧张素II的生成，并减少某些具有血管舒张作用的激肽的降解。在国外上市的卡托普利、依那普利和赖诺普利中，匈牙利仅能获得作用时间较短的卡托普利。血管紧张素转换酶抑制剂是治疗高血压和充血性心力衰竭的新方法。卡托普利在心力衰竭早期似乎有效。它可减缓甚至抑制心力衰竭的进展。已揭示出治疗的新方面。它可成功用于心绞痛、预防心肌梗死伴发的再灌注心律失常、治疗肾实质肾疾病、糖尿病肾病。还讨论了血管紧张素转换酶抑制剂的副作用、相互作用和剂量。
